Texas Failed to Secure Ibogaine Research Proposals
The state received no qualifying bids for its $50 million initiative to study ibogaine for health treatments.
Updated on Oct. 9, 2026 in Substance Abuse
Live Poll
Should the federal government provide funding to states for psychedelic drug research?
On March 31, 2026, Texas officials confirmed that the Texas Health and Human Services Commission received no qualifying proposals for state-funded ibogaine trials. The project was originally contingent on securing matching investment funds.
Why it matters
The lack of proposals stalls a $50 million effort to explore psychedelic treatments, as Texas law mandated private or federal matching investments for the initiative to proceed. This creates a significant hurdle for the state in evaluating potential clinical applications for ibogaine.
The Texas Health and Human Services Commission held a $50 million budget for ibogaine trials, but secured zero proposals. This stands against the requirement of matching investment funds necessary to activate the state-appropriated capital.
The players
Texas Health and Human Services Commission
This state agency is responsible for overseeing health and social services and managed the request for proposals for the ibogaine trials.
President Donald Trump
The current President of the United States signed an executive order directing federal agencies to partner with states on psychedelic research.
The details
The commission had opened a request for proposals to fulfill the state-funded study, but no entities met the criteria required by law. Texas now plans to pivot toward an independent research program instead of the original collaborative model.
Timeline
March 30, 2026: Texas officials announced that no research proposals were submitted.
March 31, 2026: The state confirmed the failure to secure any bids for the ibogaine study.
April 18, 2026: President Donald Trump signed an executive order regarding psychedelic research funding.
The Big Picture
This state initiative was intended to align with the Department of Health and Human Services psychedelic research grant program, which offers matching funds for state-led efforts. The failed bid process marks a departure from the state's anticipated trajectory for psychedelic medical research.
Residents seeking access to new ibogaine treatments will face delays as the state pivots from its original trial model to an independent program. There is no current timeline for when or if these research trials will become available to the public.
The takeaway
The failure to secure bids underscores the difficulty of bridging state-funded mandates with the nascent market for psychedelic research. State officials now face the challenge of developing an independent path forward without the initial matching investment structure.
Further reading
Learn more about the state's clinical initiatives by visiting the Substance Abuse section.
Source note: This article includes information reported by Columbia Gorge News.
Live Poll
Should the federal government provide funding to states for psychedelic drug research?
